Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Money Mood who wrote (1052)	3/4/2000 3:24:00 PM
From: Cacaito	Respond to of 1386

Pharmos phase II already released results from cohort-1(75 mg) and cohort-2(150 mg), these results showed good trend to decrease mortality (no statistical significance due to sample size) and showed decrease morbidity as measure by faster recovery, less disability at 6 months (statistically significant). The phaseII-cohort-3 (200 mg)is the group results are pending, the recruitment is completed and the follow up of the few last patients is almost ready (maybe ready). These are the results that are expected by the market. Pharmos is ready to start (maybe it did?)the definitive phaseII/III (in my view expect it to last 18 to 36 months to completion)with 30 multinational centers and expect it to cost some $15 to $30 millions, if a partner is found along the way to finance a larger (more centers)faster study a lot of things could changed for good. Pars starts on their own, so they will end up with a bigger piece of revenues, more leverage for negotiations, but along the way they could pick up a partner and the phaseII/III evolved on the go into a full fledge PHASE III (Pharmos plan, not my opinion). Of course, many other possibilities on the way, partners for the Tamoxifen-metabolites, partner dexanabinol for stroke indication and that way start other studies that spread risk of failure (decrease risks with multiple indications-studies on the way)emulsones... Please, notice that many are my rosy views on the long term future and that I am currently out waiting for a second entry point, since a lot of recent rise is due to the hot biotech wave. I do believe a lot on Pharmos, but I am waiting to entry with the full data out (if at all). My long term position (almost 3 years)is now sold.

To: Money Mood who wrote (1052)	3/4/2000 3:36:00 PM
From: David Israel-Rosen	Read Replies (1) \| Respond to of 1386

Nature 404, 84 - 87 (2000) ¸ Macmillan Publishers Ltd. Cannabinoids control spasticity and tremor in a multiple sclerosis model DAVID BAKER, GARETH PRYCE, J. LUDOVIC CROXFORD*, PETER BROWN?, ROGER G. PERTWEE?, JOHN W. HUFFMANõ & LORNA LAYWARD